Posters
« Back
Survival outcomes following stereotactic radiosurgery for patients with brain metastases: a single centre experience
EP30711
Poster Title: Survival outcomes following stereotactic radiosurgery for patients with brain metastases: a single centre experience
Submitted on 07 Nov 2019
Author(s): Martin R Brewer, Chiara Reverberi, Jessica Yanwube, Helen Taylor, Philippa Sturt, Michaela James, Mostafa El-Haddad, Antonia Creak, Nicola Rosenfelder, Frank Saran, Liam Welsh
Affiliations: The Royal Marsden NHS Foundation Trust
This poster was presented at BIR Annual Congress 2019
Poster Views: 57
View poster »


Poster Information
Abstract: Introduction
Stereotactic Radiosurgery (SRS) for the treatment of brain metastases is a specialist service commissioned by NHS England in May 2016 (1). Patients deemed eligible for SRS should have an expected survival of at least 6 months. This retrospective study evaluates overall survival (OS) in patients with brain metastases treated with SRS at The Royal Marsden Hospital and assesses survival according to tumour sub-type.

Methods
All patients meeting service eligibility criteria (1) treated between May 2016 and September 2018 were included in this analysis. Patients having treatment to a surgical cavity were excluded. Treatment was delivered on a CyberKnife VSI platform according to departmental protocols. OS was calculated for the entire patient cohort and three most common primary tumour types and their molecular subtypes known to affect systemic treatment options.

Results
386 patients were treated within the analysis period with a median follow-up of 9.9 months (range 1-35 months). Median OS for the entire cohort was 15.2 months. OS rates at 6, 12 and 24 months was 72.5%, 55.1% and 38.4% respectively. Median OS for breast (n=90), lung (n=162), and melanoma (n=49) primaries were 19.7, 14.8, and 15.3 months respectively. Subgroup analyses of molecular characteristics demonstrate favourable OS in patients harbouring mutations.

Conclusions
Median OS was >12 months but is <6 months in >25% of patients and this requires further analysis. Primary tumour histology and molecular subtype is likely to significantly affect OS. Sequencing and timing of SRS with newer targeted systemic therapies requires further assessment in prospective studies.
Summary: A single centre experience and outcomes of treating brain metastases with stereotactic radiosurgeryReferences: 1. NHS England (2013) Clinical Commissioning Policy: Stereotactic Radiosurgery / Radiotherapy for Cerebral Metastases https://www.england.nhs.uk/d05/Report abuse »
Creative Commons

Related Posters


Modelling recurrent event data: a comparison of the Cox proportional hazards model and three of its extensions to estimate the risk of recurrent healthcare-associated infections in critically ill patients
Evangelos I. Kritsotakis, Guillermo Castilla Fernandez, Mark Strong

Acetabular socket size templating with femoral head diameter and pelvic x-ray A novel surgical technique
Kalaivanan Kanniyan , Shantanu Patil , Ashok Kumar PS, Vijay C Bose , Suryanarayan Pitchai

ALCAPA
Dr Nesrine Hammoudi ; Dr Salim Kara Mostefa ; Dr Mokhtar Nehhal

VARIANTES ANATÓMICAS MAS FRECUENTES EN LESIÓN DE VIA BILIAR REPORTE DE TRES CASOS
Brito-Carmona R.D., Cuendis-Velázquez A., Bada Yllan O., Valenzuela-Salazar C. Campos-Badillo J.A. Serrano-Andrade F.X.

CIRUGÍA LAPAROSCÓPICA EN LA REINTERVENCIÓN EN CIRUGÍA ANTIRREFLUJO UNA REVISIÓN SISTEMÁTICA.
Campos-Badillo Julio Adan, ARCENIO LUIS VARGAS ÁVILA, JOSE ROLDAN TINOCO, ARMANDO SOTO LA MARINA BETANCOURT, SALVADOR GARCIA CIPRES, SALVADOR CHAVEZ ACEVEDO